acosamide for treatment-resistant bipolar disorder: a open-label study - Lacosamide for bipolar disorder

Kishi Taro0 个研究点目标入组 20 人开始时间: 2019年1月29日最近更新: 2023年10月17日

适应症

试验速览

acosamide improve depressive symptoms in patients with bipolar disorder.

•1. The clinical trial was described in detail to the subjects, and written informed consent was obtained from all participants and their guardians. 2. patients age: 20 > years olds and < 70 years old 3. Patients met at least 2 the following inclusion criteria -Patients did not improve their symptoms using at least one mood stabilizer with adequate dose for 4 weeks or more than 4 weeks.
•-Patients did not improve their symptoms using at least one second generation antipsychotic with adequate dose for 4 weeks or more than 4 weeks.
•-Patients did not improve their symptoms using combination therapy of mood stabilizer with second generation antipsychotic with adequate dose for 4 weeks or more than 4 weeks.

•1. patients receiving electroconvulsive therapy within 6 months prior to the study enrollment.
•2. no pregnancy, no lactation.
•3. no severe physical illness.
•4. no neurological disease.
•5. patients have suicidal ideation.
•6. patients judged that researchers are inappropriate to participate in the study

发起方

Kishi Taro